Search results for "COMB"

showing 10 items of 7115 documents

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

Small and dense LDL in Familial Combined Hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene

2009

18 pagesm 2 figures. -- PMID: 19335919 [PubMed]

AdultMalemedicine.medical_specialtyApolipoprotein BAdolescentEndocrinology Diabetes and MetabolismPopulationClinical BiochemistryHyperlipidemia Familial CombinedMutation MissenseBlood lipidschemistry.chemical_compoundYoung AdultHigh-density lipoproteinEndocrinologyInternal medicinePrevalenceMedicineShort PaperHumanseducationlcsh:RC620-627AgedBiochemistry medicalLipoprotein lipaseeducation.field_of_studyPolymorphism Geneticmedicine.diagnostic_testbiologyCholesterolbusiness.industryBiochemistry (medical)Cholesterol LDLMiddle AgedAtherosclerosisLipidslcsh:Nutritional diseases. Deficiency diseasesLipoprotein LipaseEndocrinologychemistrySpainLow-density lipoproteinCase-Control Studiesbiology.proteinFemalelipids (amino acids peptides and proteins)businessLipid profile
researchProduct

Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.

2008

Previous studies have shown that asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and nitric oxide (NO) play a prominent role in liver dysfunction. The objective of this study was to determine whether plasma levels of ADMA, SDMA and NO are altered in patients with chronic hepatitis C.Plasma levels of ADMA, SDMA and NO (nitrite plus nitrate) were measured in 22 patients with chronic hepatitis C and 24 patients with sustained virologic response after treatment with peginterferon plus ribavirin. Seven healthy volunteers served as controls.Plasma levels of ADMA, SDMA and NO were not significantly different between groups: chronic hepatitis C, ADMA 0.55+/-0.06, SDMA 0.22+/-0…

AdultMalemedicine.medical_specialtyArginineInterferon alpha-2ArginineNitric OxideAntiviral AgentsNitric oxidePolyethylene Glycolschemistry.chemical_compoundInterferonInternal medicineBlood plasmaRibavirinMedicineHumansbusiness.industryRibavirinGastroenterologyCase-control studyInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsEndocrinologychemistryCase-Control StudiesFemalebusinessAsymmetric dimethylargininemedicine.drugScandinavian journal of gastroenterology
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants

2018

Abstract Background Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. Methods Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants. Results Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hypert…

AdultMalemedicine.medical_specialtyBipolar DisorderAdolescentLithium (medication)media_common.quotation_subjectTreatment-emergent-maniaAntidepressantGastroenterologyYoung Adult03 medical and health sciencesBipolar Disorder (BD) Antidepressant Depression Treatment-emergent-mania0302 clinical medicineInternal medicineRecall biasOutpatientsmedicineHumansBipolar disorderAgedmedia_commonAntidepressant; Bipolar Disorder (BD); Depression; Treatment-emergent-mania; Clinical Psychology; Psychiatry and Mental Healthbusiness.industryDepressionMiddle Agedmedicine.diseaseBipolar Disorder (BD)Antidepressive Agents030227 psychiatryClinical PsychologyCross-Sectional StudiesTreatment OutcomeTolerabilityPsychiatry and Mental HealthAntidepressantDrug Therapy CombinationFemaleTemperamentmedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsPsychopathologymedicine.drug
researchProduct

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomograp…

2009

Abstract Purpose In the pre—positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on a response-tailored number of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) courses in 218 intermediate-stage Hodgkin lymphoma patients. Patients and Methods Patients with stage I/II showing at least one adverse prognostic factor and stage IIIA without adverse prognostic factors were recruited. Treatment included a first step of 3 ABVD courses, followed by an early-restaging. Patients in CR/CRu received 1 additional ABVD cycle, patients in PR received 3 more ABVD, and nonresponder patients went off study. Involved-fi…

AdultMalemedicine.medical_specialtyCancer ResearchAdolescentDacarbazinemedicine.medical_treatmentEarly restagingVinblastineBleomycinYoung AdultAdolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Vinblastine; Young AdultAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy Protocolmedicine.diagnostic_testbusiness.industryGeneral MedicineHematologyMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRadiation therapyDacarbazineProspective StudieABVDOncologyDoxorubicinErythrocyte sedimentation ratePositron-Emission TomographyFemaleRadiologybusinessmedicine.drugHumanClinical lymphomamyeloma
researchProduct

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

2007

Abstract Background The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival. Methods Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII). Results The overall survival was significantly more…

AdultMalemedicine.medical_specialtyCancer ResearchTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaMalignancylcsh:RC254-282Disease-Free SurvivalSurgical oncologymedicineGeneticsHumansSurvivorsEsophagusSurvival analysisAgedNeoplasm StagingRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryEsophagectomyLog-rank testTreatment Outcomemedicine.anatomical_structureOncologyEsophagectomyLymph Node ExcisionAdenocarcinomaFemalebusinessResearch ArticleBMC Cancer
researchProduct

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

2011

Abstract Background There is no consensus about the most effective method for transarterial chemoembolisation of hepatocellular carcinoma. Aim The aim of this phase II trial was to compare the efficacy and toxicity of lipiodol transarterial chemoembolisation with amiodarone in association with pirarubicin or doxorubicin versus lipiodol transarterial chemoembolisation with anthracycline alone in a control group. Methods Patients with unresectable hepatocellular carcinoma and Child-Pugh A/B7 were considered eligible for the trial. transarterial chemoembolisation was repeated every 6 weeks for a maximum of 4 sessions. Results Thirteen patients were randomised in the amiodarone group, and 14 we…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAnthracyclinePirarubicinAmiodaroneKaplan-Meier EstimateAmiodaroneGastroenterologyDisease-Free Survivallaw.inventionExcipientsEthiodized OilRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansChemoembolization TherapeuticAgedHepatologybusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseSurgeryClinical trialTreatment OutcomeDoxorubicinHepatocellular carcinomaLipiodolFemalebusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Hepatocellular carcinoma (HCC) vs. non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018

2019

PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS) was created to standardize the diagnostic criteria for hepatocellular carcinoma (HCC), and has undergone multiple revisions including a recent update in 2018 (v2018). The primary aim of this study was to determine the diagnostic performance and interrater reliability (IRR) of LI-RADS v2018 for distinguishing HCC from non-HCC primary hepatic malignancy in patients ‘at-risk’ for HCC. A secondary aim was to assess the impact of changes introduced in the v2018 diagnostic algorithm. METHODS: This retrospective study combined a 10-year experience of pathologically-proven primary liver malignancies from two large liver transplant cente…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularUrologyMalignancySensitivity and SpecificityArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overCirrhosiRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyReproducibility of ResultsRetrospective cohort studyHepatologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingInterrater reliabilitydigestive system diseasesCombined hepatocellular-cholangiocarcinoma (cHCC-CCA)030220 oncology & carcinogenesisHepatocellular carcinomaCohortLI-RADSFemaleRadiologybusinessTomography X-Ray ComputedIntrahepatic cholangiocarcinoma (iCCA)Algorithms
researchProduct

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observ…

2018

BACKGROUND: European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylprednisolone alone in patients with moderate-to-severe Graves' orbitopathy.METHODS: MINGO was an observer-masked, multicentre, block-randomised, centre-stratified trial done in two centres in Germany and two in Italy. Patients with active moderate-to-severe Graves' orbitopathy were randomly assigned to receive intravenous methylprednis…

AdultMalemedicine.medical_specialtyCombination therapyAdolescentEndocrinology Diabetes and MetabolismPopulationMedizinAnti-Inflammatory Agents030209 endocrinology & metabolismMethylprednisoloneSeverity of Illness IndexMycophenolic acidlaw.inventionGraves' ophthalmopathy03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawInternal medicineJournal ArticleInternal MedicinemedicineHumanseducationAdverse effectAgededucation.field_of_studyAntibiotics Antineoplasticbusiness.industryMiddle AgedMycophenolic Acidmedicine.diseaseDiscontinuationGraves OphthalmopathyTreatment OutcomeMethylprednisoloneItaly030221 ophthalmology & optometryDrug Therapy CombinationFemalebusinessmedicine.drugThe lancet. Diabetesendocrinology
researchProduct